MRCY Stock Draws Bullish Targets After Record Quarter

Mercury Systems Inc stocks have been trading up by 7.38 percent following major defense contract wins boosting investor confidence.

Live Update At 16:47:24 EDT: On Tuesday, September 15, 2026 Mercury Systems Inc stock [NASDAQ: MRCY] is trending up by 7.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MRCY just printed the kind of quarter traders look for when hunting momentum in defense names. Mercury Systems’ Q4 revenue hit $289.8M, well ahead of the $266.1M Wall Street expected, and up roughly 6% year over year. That top-line beat is the anchor behind the wave of target hikes.

On the bottom line, MRCY delivered adjusted EPS of $0.37, down from $0.47 a year earlier and a penny shy of consensus. So earnings growth is not the story right now. GAAP net income was only $1M in Q4, and the company reported a full‑year FY26 net loss of $30M, which shows the P&L is still under pressure.

More Breaking News

• MARA Holdings Drops As JPMorgan Slashes Price Target
• GLND Stock Rockets After US–Denmark–Greenland Security Pact
• NTSK Stock Holds Tight Range As Traders Weigh Losses And Cash Runway
• JAGX Stock Whipsaws As Rare-Disease Catalysts Meet Cash Strain

Zoom out to the chart, though, and traders see a different picture. Over the last couple of weeks, MRCY has pulled back from the mid‑$90s to the high‑$80s and low‑$80s, then bounced, closing near $87.01 on 2026/09/15. The daily candles show tight ranges and higher lows, a classic consolidation after a run. Intraday, the 5‑minute tape on the latest session shows steady grind higher from the low $80s into the high $86s–$87s into the close, a sign dip buyers are active and shorts are nervous.

Why Traders Are Watching MRCY Now

For active traders, the real story with MRCY is the order book. Mercury Systems just posted record Q4 bookings of about $660M, up an eye‑popping 93% year over year. Total backlog is now north of $1.9B, up 38% year over year, with roughly $1.0B expected to turn into revenue in the next 12 months. That kind of visibility is rare in this tape. It tells traders that demand for Mercury Systems’ defense electronics is not a one‑off spike; it is building into a multi‑year cycle.

Wall Street is responding fast. Piper Sandler lifted its MRCY target from $126 to $131 and kept an Overweight rating, pointing to the 93.1% bookings surge and the $1.945B backlog as proof this is a real inflection in demand. Canaccord followed by bumping its target to $128 from $106, calling out revenue more than 10% above estimates and strength across all major product lines. That “broad‑based” comment matters — it tells traders MRCY is not leaning on one lucky program.

RBC is in the same camp, raising its Mercury Systems target to $120 and highlighting a 2.3x book‑to‑bill ratio plus what it calls conservative FY27–FY28 guidance. Baird pushed its target to $130, Truist to $120, and Guggenheim jumped in with a fresh Buy at $115. The Street’s average target sits in the low‑$110s with an Overweight tilt. For traders, that sets up a clear sentiment backdrop: MRCY is seen as a core defense growth name, with upside tied to sustained U.S. and allied defense spending. The near‑term caveat is simple — GAAP profitability and free cash flow still lag the demand story, so the stock will likely reward execution and punish any stumble.

Conclusion

Right now, MRCY is a textbook example of a “strong fundamentals, messy earnings” setup that active traders love to study. Mercury Systems is showing powerful revenue momentum, best‑ever bookings, and a backlog that gives unusually clean visibility into the next year. That is why big shops like Piper Sandler, Canaccord, RBC, Baird, Truist, and Guggenheim are crowding to the bullish side with price targets between $115 and $131.

At the same time, the numbers under the hood remind traders not to get lazy. MRCY still runs negative GAAP margins on a full‑year basis, free cash flow slipped year over year, and stock‑based compensation is high. Those factors can cap how far valuation stretches in the short run, especially if the broader market rotates away from growth and back toward clean earnings and cash.

This is where smart trading discipline comes in. Mercury Systems has the momentum, but it also has risk. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful ones — study the pattern, know the catalyst, and always have a plan to cut losses fast.” That mindset pairs well with another key reminder for active traders: as Tim Bohen, lead trainer with StocksToTrade says, “Time and experience have taught me that missed opportunities are part of the game. There’s always another setup around the corner.” For anyone tracking MRCY, that means respecting both the bullish order book and the unfinished work on profitability, and trading the chart — not the hype.

This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

• How to Read Stock Charts: A Guide for Beginners
• Trading Plan: 6 Steps to Create One
• How To Create a Stock Watchlist

Ready to build your watchlists? Check out these curated lists:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.